Recursion Pharmaceuticals Insider Blake Borgeson Sells $155K of Stock
Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals, Inc. at $3.88 a share, worth $155K in total on Nov 3, 2026. Shares held after the trade: 6,068,287 (-0.7%).
Recursion Pharmaceuticals reported a net loss of $119.0 million for the third quarter of 2026, an improvement from the $162.3 million loss in the prior year period. Total revenue increased significantly to $18.6 million for the quarter, while the company maintained a strong liquidity position with $549.9 million in cash and cash equivalents as of September 30, 2026.
Recursion Pharmaceuticals reported Q3 2026 financial results, highlighting clinical data for REC-4881 and REC-1245 and the appointment of Fred Hassan as Chair of the Board. The company extended its cash runway into 2029 following an October follow-on offering and noted that Sanofi has optioned the first development candidate from their collaboration.
Term
Q3 2026
“To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients.”
Najat Khan, Ph.D., President and Chief Executive Officer of Recursion